Reismüller Bettina, Steiner Manuel, Pichler Herbert, Dworzak Michael, Urban Christian, Meister Bernhard, Schmitt Klaus, Pötschger Ulrike, König Margit, Mann Georg, Haas Oskar A, Attarbaschi Andishe
Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
Children's Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung, Vienna, Austria.
Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26327. Epub 2016 Nov 2.
Approximately 30% of childhood acute lymphoblastic leukemia (ALL) cases are high hyperdiploid (HD). Despite their low relative recurrence risk, this group accounts for the overall largest relapse proportion.
To evaluate potential risk factors in our population-based cohort of patients with HD ALL enrolled in four Austrian ALL-BFM (Berlin-Frankfurt-Münster) studies from 1986 to 2010 (n = 210), we reviewed the clinical, laboratory, and cytogenetic data of the respective cases in relation to their outcome.
The 5-year event-free (EFS) and overall survival (OS) of the entire group was 83.1 ± 2.7% and 92.0 ± 1.9%, respectively. Univariate analysis revealed that trisomy 17 was significantly associated with a better EFS and OS, whereas trisomy 10 and a modal chromosome number (MCN) > 53 chromosomes were significantly associated with a better OS. Except for the latter, findings remained valid in multivariate analysis.
In line with previous studies, our retrospective analysis shows that MCN and specific trisomies are relevant prognostic indicators in an ALL-BFM cohort of patients with HD ALL. However, considering the current dominant role of minimal residual disease monitoring for prognostic stratification in ALL, including this particular subgroup, it is unlikely that this information is compelling enough to be utilized for refined risk classification in future ALL-BFM treatment protocols.
约30%的儿童急性淋巴细胞白血病(ALL)病例为高超二倍体(HD)。尽管其相对复发风险较低,但该组在总体复发比例中占比最大。
为评估1986年至2010年参加四项奥地利ALL-BFM(柏林-法兰克福-明斯特)研究的HD ALL患者基于人群队列中的潜在风险因素(n = 210),我们回顾了各病例的临床、实验室和细胞遗传学数据及其结局。
整个组的5年无事件生存(EFS)率和总生存率(OS)分别为83.1±2.7%和92.0±1.9%。单因素分析显示,17号染色体三体与更好的EFS和OS显著相关,而10号染色体三体和众数染色体数(MCN)>53条染色体与更好的OS显著相关。除后者外,多因素分析结果仍然有效。
与先前研究一致,我们的回顾性分析表明,MCN和特定三体是HD ALL患者ALL-BFM队列中的相关预后指标。然而,考虑到目前微小残留病监测在ALL预后分层中的主导作用,包括这个特定亚组,这些信息不太可能有足够的说服力用于未来ALL-BFM治疗方案中的精细风险分类。